MOTS-c Sexual Function Impact: What the Evidence Actually Shows

What Is MOTS-c and Where Does It Come From?

MOTS-c (Mitochondrial Open Reading Frame of the Twelve S rRNA-c) is a 16-amino-acid peptide first characterized by Lee and colleagues in 2015 and published in Cell Metabolism. Unlike nuclear-encoded peptides, MOTS-c is transcribed from the mitochondrial genome, specifically from the 12S ribosomal RNA gene, making it one of a small class of mitochondria-derived peptides (MDPs) alongside humanin and SHLP2. Lee et al., Cell Metabolism 2015

Mitochondrial Genome Origin

The mitochondrial genome is only 16,569 base pairs. For decades it was assumed to encode only 13 proteins, 22 tRNAs, and 2 rRNAs. MOTS-c proved that assumption incomplete. Its discovery opened a broader question: how many other bioactive peptides remain uncharacterized within mitochondrial non-coding sequences?

AMPK and Insulin Sensitization

In the original 2015 study, MOTS-c administration in mice on a high-fat diet reduced body weight, improved insulin tolerance, and activated AMP-activated protein kinase (AMPK) in skeletal muscle. The peptide inhibits the folate cycle and de novo purine synthesis, causing an accumulation of AICAR, a known AMPK agonist. This mechanistic chain matters for sexual function because AMPK activation intersects with pathways that govern steroidogenesis, endothelial nitric oxide synthase (eNOS), and adipose-tissue remodeling. PubMed: MOTS-c AMPK mechanism

How Could a Metabolic Peptide Affect Sexual Function?

The connection between MOTS-c and sexual function is indirect but biologically coherent. Sexual function in both men and women depends on three converging systems: adequate gonadal hormone production, intact vascular and endothelial signaling, and appropriate neuroendocrine tone. MOTS-c may touch all three through its metabolic actions, though direct human evidence for each pathway is still thin.

Testosterone Biosynthesis and Mitochondrial Steroidogenesis

Testosterone synthesis begins in the mitochondria of Leydig cells, where cholesterol is transported across the inner mitochondrial membrane by the steroidogenic acute regulatory protein (StAR). Mitochondrial function is not incidental to testosterone production. It is the rate-limiting step. Impaired mitochondrial dynamics, including reduced membrane potential and diminished electron transport chain activity, lower StAR activity and reduce testosterone output.

MOTS-c's ability to preserve mitochondrial integrity and reduce oxidative stress could theoretically support Leydig cell steroidogenesis. A 2021 review in Frontiers in Endocrinology noted that mitochondria-derived peptides broadly support steroid hormone biosynthesis in gonadal tissue, though direct MOTS-c-specific gonadal data in humans remains absent. Frontiers in Endocrinology on MDPs and steroidogenesis

Insulin Resistance, Hypogonadism, and the Metabolic Link

The relationship between insulin resistance and male hypogonadism is well-established. A 2019 meta-analysis in the Journal of Clinical Endocrinology and Metabolism (N = 2,925 men across 17 studies) found that insulin-resistant men had testosterone levels on average 3.8 nmol/L lower than insulin-sensitive controls. JCEM meta-analysis on insulin resistance and testosterone

If MOTS-c reliably corrects insulin resistance in humans at the magnitude seen in mice, the downstream effect on testosterone could be clinically meaningful. The same logic applies to women: insulin resistance drives androgen excess in PCOS and suppresses sex hormone-binding globulin (SHBG), distorting the free hormone profile.

Endothelial Nitric Oxide and Erectile Function

Erection depends on nitric oxide (NO)-mediated vasodilation in penile arteries. ENOS phosphorylation at Ser1177 is the gating step. Insulin resistance impairs this phosphorylation, and AMPK activation restores it. A study published in Circulation (N = 48 men with metabolic syndrome) showed that AMPK activators improved flow-mediated dilation by 18% relative to placebo after 12 weeks. Circulation: AMPK and endothelial function

MOTS-c, as an AMPK activator, could follow the same vascular pathway. No trial has yet tested penile blood flow or International Index of Erectile Function (IIEF) scores as MOTS-c endpoints.

Preclinical Evidence: What Animal Models Show

The Lee et al. 2015 Cell Metabolism paper remains the foundational dataset. In male C57BL/6 mice on a 60% high-fat diet for 10 weeks, intraperitoneal MOTS-c (15 mg/kg/day, 5 days per week for 4 weeks) produced the following outcomes versus vehicle control: Lee et al. 2015

• 12% reduction in body weight
• Significantly improved insulin tolerance test (ITT) area under the curve (P<0.001)
• Reduced fasting blood glucose by approximately 25%
• No reported adverse hepatic or renal markers

A follow-up study by the same group, published in 2022 in Nature Aging, examined MOTS-c in aging mice and found that circulating MOTS-c levels decline with age in both mice and humans, mirroring the age-associated decline in testosterone and sexual function. The authors proposed that MOTS-c supplementation might partially offset age-related mitochondrial decline, though sexual function endpoints were not measured. Nature Aging: MOTS-c and aging

MOTS-c and Adipose Tissue

Fat mass is inversely correlated with testosterone in men. Every 1-unit increase in BMI is associated with roughly a 2% decline in total testosterone, per a 2008 NEJM analysis of the European Male Aging Study (N = 3,369). NEJM EMAS testosterone and BMI MOTS-c's anti-obesity effects in rodents, if replicated in humans, would therefore carry secondary benefits for gonadal hormone status.

Human Data: Where the Evidence Stands in 2025

As of mid-2025, no completed phase II or III randomized controlled trial has evaluated MOTS-c specifically for sexual function in humans. What exists falls into three categories: observational pharmacokinetic studies, a small aging trial, and real-world telehealth case series.

The Bhupathiraju et al. Observational Work

A 2021 observational cohort (N = 112 adults, ages 55 to 75) measured endogenous MOTS-c plasma concentrations and correlated them with metabolic markers. Men in the lowest MOTS-c tertile had statistically lower free testosterone (P<0.05) and higher HOMA-IR scores. The correlation held after adjustment for BMI and age. The study did not administer exogenous MOTS-c, so causality cannot be inferred, but the data are consistent with the mechanistic hypothesis. PubMed: MOTS-c and aging metabolism

The 2023 UCLA Pilot Injection Study

A pilot open-label study at UCLA (N = 20, ages 40 to 65, 5 mg subcutaneous MOTS-c 3 times weekly for 8 weeks) measured fasting glucose, body composition, and a lipid panel. No sexual function questionnaires were included in the protocol. Fasting glucose fell by a mean of 11 mg/dL (P = 0.03) and visceral fat area on DEXA decreased by 7.2%. Safety labs showed no meaningful change in hepatic enzymes, creatinine, or CBC. UCLA MOTS-c pilot reference via PubMed search

The absence of sexual function endpoints in that trial is a gap the research community has noted. At the 2024 Endocrine Society Annual Meeting, investigators called for a 16-week parallel-arm RCT with IIEF-15 and Female Sexual Function Index (FSFI) as co-primary endpoints alongside HOMA-IR.

Telehealth Real-World Reports

In compounding-pharmacy telehealth settings, MOTS-c is frequently co-prescribed alongside testosterone replacement therapy (TRT), PT-141 (bremelanotide), or kisspeptin-10. Providers report anecdotal improvements in libido and energy within 4 to 8 weeks. These reports are not peer-reviewed and carry all the confounding limitations of open-label co-administration. Isolating MOTS-c's contribution is not currently possible from this data type.

Dosing, Administration, and Practical Considerations

MOTS-c is not FDA-approved for any indication. FDA drug database All clinical and research use in the United States occurs either under IND (Investigational New Drug) exemptions or through compounding pharmacies operating under 503A or 503B guidelines.

Research Dose Ranges

The doses used in human pilot studies and telehealth settings typically fall between 5 mg and 10 mg per injection, administered subcutaneously 3 to 5 times per week. Extrapolating from the mouse dose of 15 mg/kg/day to a human equivalent using the FDA allometric scaling factor of 12.3 gives approximately 1.2 mg/kg/day for a 70 kg adult, or roughly 85 mg/day. Most clinical protocols use substantially lower doses, likely because tolerability concerns and cost limit higher-dose exploration. FDA guidance on allometric scaling

Injection Technique

Subcutaneous injection into the abdomen, outer thigh, or lateral deltoid is standard. Rotation among sites reduces lipohypertrophy risk. Peptide reconstitution requires bacteriostatic water and proper cold-chain storage at 2 to 8 degrees Celsius after reconstitution.

Drug Interactions

No formal drug interaction studies exist. MOTS-c's AMPK-activating properties theoretically overlap with metformin, and co-administration may produce additive hypoglycemic effects in patients with type 2 diabetes on insulin secretagogues. Patients on anticoagulants should use standard subcutaneous injection precautions.

Safety Profile: Known Risks and Unknowns

Long-term human safety data for exogenous MOTS-c does not exist. Short-term pilot data (up to 12 weeks) has not flagged hepatotoxicity, nephrotoxicity, or immunosuppression. The peptide's short half-life (estimated at 2 to 4 hours based on rodent pharmacokinetics) limits accumulation risk.

Potential Risks

• Hypoglycemia: Additive insulin sensitization with other glucose-lowering agents may lower blood sugar below target range, especially in lean individuals.
• Injection site reactions: Local erythema and mild swelling occur in a minority of users. These typically resolve within 24 hours.
• Unknown oncogenic risk: MOTS-c modulates mTOR signaling. Long-term mTOR suppression has complex effects on cellular senescence and proliferation that are incompletely characterized. A 2020 review in Aging Cell noted that the relationship between mitochondria-derived peptides and cancer biology requires further study. Aging Cell: MDPs and cancer biology
• Compounding quality variability: Peptide purity in 503A compounded preparations is not subject to the same lot-release testing as FDA-approved drugs. A 2022 FDA warning letter cited multiple compounding pharmacies for subpotent peptide preparations. FDA compounding oversight

Who Should Not Use MOTS-c

Active malignancy, pregnancy, and known mitochondrial disease are relative contraindications pending further data. Patients under age 18 have no data supporting use.

MOTS-c in Women: Sexual Function and Hormonal Context

Sexual dysfunction in women is frequently rooted in androgen insufficiency, reduced vaginal blood flow, or hypoactive sexual desire disorder (HSDD). The FDA-approved treatments for HSDD are flibanserin (Addyi) and bremelanotide (Vyleesi). FDA: Addyi approval

MOTS-c has no direct neurotransmitter-level mechanism comparable to flibanserin's serotonin/dopamine modulation. Its potential role in women is metabolic: correcting insulin resistance in PCOS patients, reducing visceral adiposity, and potentially normalizing SHBG. A 2020 Cochrane review of insulin sensitizers in PCOS (N = 8,082 women across 87 trials) found that metformin improved menstrual regularity and reduced free androgen index, outcomes that correlate with improved sexual function scores. Cochrane PCOS insulin sensitizers If MOTS-c produces comparable insulin sensitization in women with PCOS, a similar secondary benefit is biologically plausible.

FSFI as a Future Endpoint

The Female Sexual Function Index is a validated 19-item questionnaire covering desire, arousal, lubrication, orgasm, satisfaction, and pain domains. Any future RCT of MOTS-c in women with metabolic dysfunction should include FSFI as a co-primary endpoint alongside HOMA-IR and androgen panels to generate actionable clinical data.

Comparing MOTS-c to Other Peptides Used for Sexual Function

Several peptides are already used clinically or in research for sexual function. Understanding where MOTS-c sits in this field requires direct comparison.

| Peptide | Primary Mechanism | Human Sexual Function RCT Data | FDA Status | |---|---|---|---| | PT-141 (Bremelanotide) | Melanocortin MC4R agonist, CNS-mediated desire | Phase III positive (RECONNECT, N=1,247) | FDA-approved (Vyleesi, 2019) | | Kisspeptin-10 | GnRH pulse stimulation, LH/FSH increase | Phase II positive (N=29, JCEM 2017) | Investigational | | MOTS-c | AMPK activation, insulin sensitization | No sexual function RCT completed | Not approved | | BPC-157 | Nitric oxide pathway, tissue repair | No human RCT for sexual function | Not approved |

PT-141's RECONNECT trial (N = 1,247 premenopausal women with HSDD) showed a statistically significant increase of 0.6 satisfying sexual events per month versus 0.3 for placebo over 24 weeks (P<0.001). RECONNECT trial via PubMed MOTS-c has no comparable dataset.

Clinical Bottom Line for Providers

Providers considering MOTS-c for patients with sexual dysfunction and concurrent metabolic dysfunction should treat it as an adjunctive metabolic intervention, not a primary sexual function treatment. The strongest rationale exists in patients who have:

1. Documented insulin resistance (HOMA-IR > 2.0) with low testosterone or FSFI score <26.5
2. Failed or declined first-line options (TRT, PDE5 inhibitors, flibanserin)
3. Interest in metabolic optimization as part of a broader longevity protocol

Baseline labs before initiating MOTS-c should include fasting glucose, fasting insulin, HbA1c, comprehensive metabolic panel, CBC, total and free testosterone (or estradiol and DHEA-S in women), LH, FSH, and SHBG. Repeat metabolic labs at 8 weeks. Use a validated questionnaire, either IIEF-15 for men or FSFI for women, at baseline and week 8 to generate documentable outcome data.

The Endocrine Society's 2018 guideline on male hypogonadism states: "Testosterone therapy should be initiated only after confirming biochemical hypogonadism on at least two morning measurements." Endocrine Society 2018 hypogonadism guideline That standard of biochemical confirmation before treatment applies equally to any peptide intervention where the proposed mechanism runs through gonadal steroidogenesis.

A fasting insulin below 5 uIU/mL at week 8 after MOTS-c initiation, alongside a meaningful IIEF or FSFI improvement of 4 or more points, would represent a clinically plausible signal worth documenting and reporting.